ABPRO HOLDINGS INC C/WTS 12/11/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.05

EPS: As of FY2025 Q2, the actual value is USD -0.05.

Segment Revenue

• The company did not generate revenue during the three and six months ended June 30, 2025, and 2024.

Operational Metrics

• Net Loss: The net loss for the three months ended June 30, 2025, was $2,984,000, compared to $2,440,000 for the same period in 2024, representing a 22% increase.
• Research and Development Expenses: Decreased by 62% to $313,000 for the three months ended June 30, 2025, from $827,000 in the same period in 2024.
• General and Administrative Expenses: Increased by 29% to $1,948,000 for the three months ended June 30, 2025, from $1,513,000 in the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended June 30, 2025, was $3,105,000, a decrease from $4,218,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, was $2,142,000, compared to $3,559,000 for the same period in 2024.

Unique Metrics

• Convertible Notes: The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., issuing convertible promissory notes totaling $5,000,000, with $3,000,000 issued in November 2024 and $2,000,000 in June 2025.

Future Outlook and Strategy

• Core Business Focus: The company plans to initiate clinical trials for ABP-102 in the first half of 2026, focusing on HER2+ solid tumors, and for ABP-201, depending on future funding availability.
• Non-Core Business: The company is exploring additional funding through equity and debt financings, collaboration agreements, and research grants to support its operations and strategic initiatives.